183 related articles for article (PubMed ID: 33260548)
1. Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b
Indra R; Vavrová K; Pompach P; Heger Z; Hodek P
Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33260548
[TBL] [Abstract][Full Text] [Related]
2. Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation.
Indra R; Pompach P; Martínek V; Takácsová P; Vavrová K; Heger Z; Adam V; Eckschlager T; Kopečková K; Arlt VM; Stiborová M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295928
[TBL] [Abstract][Full Text] [Related]
3. The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib.
Vavrová K; Indra R; Pompach P; Heger Z; Hodek P
Biomed Pharmacother; 2022 Jan; 145():112391. PubMed ID: 34847475
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome
Stiborová M; Indra R; Frei E; Kopečková K; Schmeiser HH; Eckschlager T; Adam V; Heger Z; Arlt VM; Martínek V
Monatsh Chem; 2017; 148(11):1983-1991. PubMed ID: 29104319
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
Inui H; Maeda A; Ohkawa H
Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
[TBL] [Abstract][Full Text] [Related]
7. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
[TBL] [Abstract][Full Text] [Related]
8. Oxidation of 3-aminobenzanthrone, a human metabolite of carcinogenic environmental pollutant 3-nitrobenzanthrone, by cytochromes P450 - similarity between human and rat enzymes.
Mizerovska J; Dracinska H; Arlt VM; Schmeiser HH; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():52-9. PubMed ID: 20027145
[TBL] [Abstract][Full Text] [Related]
9. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Locuson CW; Wienkers LC; Jones JP; Tracy TS
Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
[TBL] [Abstract][Full Text] [Related]
11. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
12. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes.
Stiborová M; Martínek V; Rýdlová H; Hodek P; Frei E
Cancer Res; 2002 Oct; 62(20):5678-84. PubMed ID: 12384524
[TBL] [Abstract][Full Text] [Related]
13. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
14. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
[TBL] [Abstract][Full Text] [Related]
15. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
Huskey SW; Dean DC; Miller RR; Rasmusson GH; Chiu SH
Drug Metab Dispos; 1995 Oct; 23(10):1126-35. PubMed ID: 8654202
[TBL] [Abstract][Full Text] [Related]
16. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
[TBL] [Abstract][Full Text] [Related]
17. In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone.
Yan Z; Caldwell GW; Wu WN; McKown LA; Rafferty B; Jones W; Masucci JA
Xenobiotica; 2002 Nov; 32(11):949-62. PubMed ID: 12487725
[TBL] [Abstract][Full Text] [Related]
18. Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b
Gómez-Tabales J; García-Martín E; Agúndez JAG; Gutierrez-Merino C
Sci Rep; 2020 Sep; 10(1):15571. PubMed ID: 32968106
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
[TBL] [Abstract][Full Text] [Related]
20. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast.
Hayashi K; Sakaki T; Kominami S; Inouye K; Yabusaki Y
Arch Biochem Biophys; 2000 Sep; 381(1):164-70. PubMed ID: 11019832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
